Economic Atlas
WORKSPACE
OverviewScreenerWatchlistChatAccount
EXPLORE
CompaniesPlacesPlace screenerMethodology
Terms·Privacy
Economic Atlas
HomeScreenerChatCompanies
Economic Atlas
WORKSPACE
OverviewScreenerWatchlistChatAccount
EXPLORE
CompaniesPlacesPlace screenerMethodology
Terms·Privacy
Economic Atlas
Companies/NextCure, Inc.
Company profile

NextCure, Inc.

NASDAQ: NXTC · Healthcare · Biotechnology
PublicHQ Beltsville, MD · Prince George'sCIK 0001661059Reports USD
#529 of 1,394 Healthcare companies by revenuetop-decile growth
EA Score
37D
FH 32DQ 44GM —SS 42
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), filing timeliness · ↓ Piotroski F, disclosure history
Methodology →
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$55.8M
Employees
43
Market cap
$5.0M
OverviewFinancialsSegmentsFilingsESGPeople & Places

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$22.4M$22.4M2020
Net income-$55.8M-$55.8M2025
Operating income-$57.6M-$57.6M2025
Total assets$50.2M$50.2M2025
Liabilities$15.2M$15.2M2025
Equity$34.9M$34.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

NextCure, Inc. booked $22.4M in FY2020 revenue, growing 253% year over year — faster than 90% of Healthcare companies we track, at a -249.5% net margin.

Peers · Healthcare
GT Biopharma, Inc.32DQuest PharmaTech Inc.——Alaunos Therapeutics, Inc.33DUnidoc Health Corp.——
Neighbors
Prince George's →
IonQ, Inc.$130.0M52DLandmark Land Company, Inc.$12.2M——
Key facts
CEOMichael S. Richman
SectorHealthcare
IndustryBiotechnology
HeadquartersBeltsville, MD
ExchangeNASDAQ: NXTC
Employees43
IPO date2019-05-09
Latest filings
8-K2026-06-258-K2026-06-0110-Q2026-05-078-K2026-05-07DEF 14A2026-04-248-K2026-03-0510-K2026-03-058-K2026-01-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.
HomeScreenerChatCompanies